The primary purpose of Ketofen LP is to provide sustained symptomatic relief by managing symptoms related to physical discomfort, inflammation, and systemic imbalance across specific clinical domains. The formulation supports the maintenance of supportive relief across the daily dosing interval. The medication is generally used to address symptoms associated with conditions such as rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, acute gout, and dysmenorrhea.

---

Symptomatic Support

This medication is commonly used for the long-term, supportive management of conditions characterized by persistent inflammation and pain in conditions involving inflammatory or irritative processes. It helps ease symptom clusters that include symptoms related to physical discomfort, associated swelling, and stiffness that interferes with daily functioning, contributes to easing the overall symptom load during periods of heightened symptoms. It is also applied in acute scenarios, such as pain following post-procedural discomfort or musculoskeletal trauma.

Quick Fact: Relief for Joint Pain and Stiffness The medication is considered relevant in chronic conditions where persistent symptoms like stiffness and pain interfere with routine activities, assists with maintaining functional stability and supports general well-being during symptomatic phases.

Regulatory References

1. NIH DailyMed label for Ketoprofen extended-release capsules

Eligibility Map: Who can and cannot use Ketofen LP — Official Regulatory Information

The following statements outline the official population eligibility and non-eligibility status for Ketofen LP (Ketoprofen prolonged-release hard capsule) as defined by government regulatory agencies.

---

Populations for whom use is contraindicated (Absolute Non-Eligibility):

• Patients with known hypersensitivity to ketoprofen, aspirin, or any other Non-Steroidal Anti-Inflammatory Drug (NSAID) [Source 1.5, 3.3].
• Patients with active peptic ulceration, a history of gastrointestinal bleeding, or perforation [Source 1.5].
• Patients with severe hepatic failure, severe renal failure, or severe uncontrolled heart failure [Source 1.5].
• Patients with active bleeding (e.g., cerebrovascular or gastrointestinal) [Source 1.5].
• Patients in the third trimester of pregnancy or for the treatment of perioperative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery [Source 1.5, 3.5].

---

Age-Related Eligibility Rules:

• The medicine is not recommended for children under 15 or 18 years, as safety and efficacy have not been established in the pediatric population [Source 1.5, 3.4].
• Geriatric patients require particular caution and monitoring due to an increased risk of serious adverse events [Source 3.3].

---

Condition-Specific Restrictions (Conditional Eligibility):

• Use is generally not recommended for women attempting to conceive due to potential impairment of fertility [Source 1.5].
• Patients with non-severe renal or hepatic impairment or a history of congestive heart failure should be treated with caution and under close monitoring [Source 1.5].

---

Connection to the overall eligibility profile: Regulatory documents strictly define who can and cannot use Ketofen LP by establishing clear absolute non-eligibility criteria related to organ failure and allergic history, and by setting conditional eligibility for age groups (elderly) and patients with pre-existing conditions like cardiovascular disease. These official population restrictions serve as the regulatory basis for the medicine's approved scope of use, explicitly excluding high-risk groups and populations where safety data is insufficient.

Interactions with other medicines and products

Ketofen LP’s regulatory profile is defined by specific interactions that increase risk or alter the systemic exposure of co-administered agents.

Interaction Restrictions

Co-administration with other NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), including COX-2 inhibitors and high-dose salicylates, is formally contraindicated due to the documented heightened risk of gastrointestinal adverse events. Use is also prohibited in the perioperative setting for Coronary Artery Bypass Graft (CABG) surgery.

Documented Pharmacodynamic and Exposure Interactions

Interacting Agent	Official Regulatory Statement
Anticoagulants (e.g., Warfarin, Heparin), Antiplatelet Agents, Corticosteroids, SSRIs	Increases the risk of bleeding and gastrointestinal ulceration.
Diuretics / ACE Inhibitors	May diminish the antihypertensive or natriuretic effect and increase the risk of acute renal failure. Elderly patients are noted to be at a greater risk of this renal consequence.
Lithium / Methotrexate	Results in reduced clearance and subsequent elevation of the co-administered drug’s serum levels.
Probenecid	Reduces the plasma clearance of Ketoprofen, resulting in increased systemic exposure.

Non-Medicinal Substance Interactions

Co-administration with alcohol or specific herbal products (e.g., Ginkgo) increases the documented risk of gastrointestinal hemorrhage. While food slows the rate of absorption, it does not affect the overall extent of exposure.

Molecular Blockade of Cyclooxygenase (COX)

Ketofen LP's active component is a non-selective competitive inhibitor of the Cyclooxygenase (COX) enzymes, targeting both the constitutive COX-1 and inducible COX-2 isoforms. This direct molecular blockade curtails the biochemical cascade that processes arachidonic acid, resulting in a significant reduction in the cellular synthesis of prostaglandins and related inflammatory mediators.

Modulation of Nociceptive and Thermal Signaling

The reduction in prostaglandin levels initiates two primary physiological changes. Peripherally, the mechanism limits the chemical sensitization of nociceptors (pain fibers) at sites of injury, thereby modulating the transmission of nociceptive impulses. Centrally, this action extends to the hypothalamus, preventing pyresis-inducing prostaglandins from pathologically resetting the body’s temperature set point. This central and peripheral mechanism contributes to the attenuation of inflammatory signaling and normalization of the thermal regulatory center.

Inherent Mechanistic Constraints

The action is focused exclusively on modulating the synthesis of chemical mediators. The mechanism does not engage with or alter the underlying pathology causing tissue damage. Nociceptive signaling not dependent on eicosanoid mediation exhibits lower pathway relevance to this inhibitory mechanism.

Ketofen LP is a prolonged-release formulation of ketoprofen intended solely for oral administration. It is administered as a 200 mg hard capsule, which also represents the maximum recommended daily dose for this specific formulation. The standard regimen requires the capsule to be taken once daily, a frequency pattern designed to provide sustained relief throughout the 24-hour dosing interval. The use of this formulation is generally reserved for the long-term management of chronic inflammatory conditions, rather than for acute episodes of pain.

Procedural Constraints

The efficacy of the prolonged-release design depends on proper ingestion: the capsule must be swallowed whole and is not to be crushed or chewed. Compromising the physical integrity of the capsule would disrupt the controlled-release mechanism. To reduce the potential for gastrointestinal discomfort, the dose is typically taken with food, milk, or antacids. In the event of a missed scheduled dose, the prescribed instruction is to skip the missed dose and resume the regular schedule, rather than taking a doubled dose.

Population-Specific Use

Usage principles include adjustments for specific populations. For older adults, treatment typically begins with a reduced dosage. Similarly, patients with existing renal or hepatic impairment require a monitored reduction, with maximum daily dose limits specified to maintain the minimal effective dose. Use in pediatric patients (under 18 years of age) is not authorized, as efficacy and safety have not been established.

Research evidence / Overview of Studies for Ketofen LP

Evidence for Use in Rheumatoid Arthritis

Research has explored the use of the active ingredient in studies examining how symptoms change over time for patients with rheumatoid arthritis, a condition characterized by chronic inflammation and functional limitations. The core evidence base includes Randomized Controlled Trials (RCTs) and Systematic Reviews that compare its use against inactive treatment or other medications.

Researchers primarily monitored outcomes related to pain intensity, the severity and duration of morning stiffness, and measurements of daily functioning or activity level. What remains uncertain are the gaps in long-term data from comparative RCTs, as follow-up durations were limited in many key trials, and research provides limited insight into how functional outcomes evolve over many years.

Evidence for Use in Osteoarthritis

The research on Ketofen LP's active ingredient in osteoarthritis was evaluated in studies focusing on chronic joint pain and symptoms related to functional imbalance. The evidence structure includes RCTs that compare the active ingredient to other agents or inactive substances in adult patients with osteoarthritis of the hip and/or knee. Bioequivalence studies are used to relate the prolonged-release (LP) form to the established data for the standard immediate-release product.

Studies explored outcomes related to physical discomfort and daily functioning, reporting on measured changes in pain relief scores and observations related to joint mobility and stiffness. A key limitation is that the efficacy findings for the LP formulation often rely on its confirmed bioequivalence, and comparative evidence is lacking for numerous, long-term RCTs focusing independently on the prolonged-release delivery system.

Evidence in Specific Populations and Research Gaps

Research has explored the use of the active ingredient in older adults. In contrast, data for certain groups remain insufficient, as official regulatory summaries have noted a lack of appropriate studies on the use of the active ingredient in the pediatric population. Therefore, results apply only to the populations studied, primarily adults, and research does not determine whether an individual outside of the studied adult population will respond similarly.

The overall evidence base presents limitations: comparative evidence is lacking in some areas, and long-term outcomes are not fully established by extensive high-quality RCTs, especially concerning changes in function spanning many years.

Key Studies & References

1. Ketoprofen Extended-Release Capsules Official Labeling and Patient Information
2. Pharmacokinetics and Bioequivalence Study of Prolonged-Release vs. Immediate-Release Ketoprofen Formulations in Healthy Volunteers

Common questions about Ketofen LP (FAQ)

Q: Why is Ketofen LP sometimes prescribed over other drugs in its class?

A: Ketofen LP is designed as a prolonged-release dosage form, which is a key difference from immediate-release medicines. This specific design controls the rate at which the drug is absorbed by the body. This approach allows for a once-daily dosing schedule, which is intended to provide sustained relief over the 24-hour period.

Q: Does Ketofen LP cause stomach issues more often than other drugs I've taken?

A: Official warnings note that Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in general are associated with a documented risk of serious gastrointestinal events, such as bleeding and ulceration, which may occur without warning symptoms. Regulatory product information emphasizes that this is a known risk for the entire class of NSAID medications.

Q: What happens if I miss a scheduled time for taking Ketofen LP?

A: The official instruction for a missed dose is to skip it and resume the next regular dose as scheduled. Taking a doubled dose to compensate for the missed one is advised against in regulatory guidance, consistent with the principle of not exceeding the daily dosage limit.

Q: Can Ketofen LP be used while breastfeeding?

A: Official documents note that the use of the active ingredient during breastfeeding has not been studied sufficiently to determine its safety profile in this setting. For this reason, use while breastfeeding is generally not recommended in official product information.

Q: Why do official documents mention that Ketofen LP should be taken with food?

A: Regulatory documents advise taking the dose with food, milk, or antacids. The purpose of this advice is to help lessen the potential for gastrointestinal discomfort or irritation that may be experienced with the medication.

Q: What is the key difference between Ketofen LP and immediate-release versions of the drug?

A: The key difference is in the release mechanism. Ketofen LP is a prolonged-release formulation engineered to deliver the active ingredient over an extended time. This contrasts with immediate-release versions, which release the medication quickly and often require a multi-dose schedule per day.

Q: How long does the effect of Ketofen LP typically last?

A: Due to its prolonged-release design, the formulation is intended to provide sustained symptomatic relief throughout the 24-hour dosing interval. This design allows the drug’s effects to be maintained until the next scheduled dose.

Q: What does the term 'long-acting' mean in the context of Ketofen LP?

A: The term 'long-acting' refers to the prolonged-release (LP) design of the capsule. This design controls the rate of drug absorption, allowing for a single daily dose and a sustained pharmacological effect.

Q: How long does it usually take for Ketofen LP to start working?

A: The time it takes for the drug to reach its highest level in the bloodstream is described in official pharmacokinetic data. For the prolonged-release capsule, peak plasma levels are typically reached around 6 to 7 hours after the dose is taken.

Q: What conditions, besides its main uses, is Ketofen LP sometimes mentioned for?

A: The active ingredient in Ketofen LP is officially indicated for managing the signs and symptoms of specific chronic inflammatory conditions. These core indications include rheumatoid arthritis and osteoarthritis.

Q: Is there a maximum time frame for how long Ketofen LP can be taken?

A: While the drug is indicated for chronic conditions, regulatory warnings advise using the lowest effective dose for the shortest duration consistent with individual treatment goals. This caution is due to the risk of serious cardiovascular events that may increase with the duration of use.

Q: Is it possible for Ketofen LP to cause an allergic reaction?

A: Yes, official documents state that the medication can cause a severe allergic reaction (hypersensitivity). The drug is formally contraindicated for use in patients who have a known history of an allergic reaction to this medication or to other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).

Q: What are the signs of a serious side effect from Ketofen LP that require attention?

A: Official patient information lists several signs that may indicate a serious side effect. These include the presence of black or tarry stools (a sign of GI bleeding), experiencing chest pain or shortness of breath (cardiovascular events), or observing yellowing of the skin or eyes (a sign of liver problems).

Q: Can Ketofen LP be taken on an empty stomach?

A: Regulatory documents advise taking the dose with food, milk, or antacids to reduce the risk of gastrointestinal discomfort. Taking the dose with food is the administration method noted in official guidance.

Q: How is Ketofen LP generally eliminated from the body?

A: The active ingredient in Ketofen LP is primarily processed in the liver. It is then eliminated from the body mostly via the urine in the form of inactive breakdown products, or metabolites.

Q: Why is the maximum recommended usage period for Ketofen LP often short?

A: The official caution regarding the duration of use is directly connected to warnings about the potential for serious cardiovascular thrombotic events, such as a heart attack or stroke. The risk of these events is noted in regulatory documents as potentially increasing with the duration of use.

Q: Are there any specific dietary restrictions mentioned for Ketofen LP?

A: Official information specifically notes that co-administration with alcohol increases the risk of gastrointestinal bleeding. Additionally, certain herbal products (such as Ginkgo) are mentioned as potentially increasing this same risk.

Q: Does taking Ketofen LP impact fertility, as described in official documents?

A: Official documents state that the use of the drug may impair female fertility. For this reason, the medication is generally not recommended for women who are actively attempting to conceive.

The official regulatory documents specify strict conditions for the storage and disposal of Ketofen LP (ketoprofen prolonged-release capsules).

Required Storage Conditions

The medication must be stored at controlled room temperature, specifically between 20°C and 25°C (68°F and 77°F). It is required to be kept in a light-resistant container and the container must be kept tightly closed to maintain product stability and integrity. The product must be dispensed with a child-resistant closure and must always be kept out of the sight and reach of children.

Disposal Instructions

To dispose of unused or expired medication, it is recommended to utilize a community drug take-back program. If this option is not available, the medication must be secured for household disposal by mixing it with an unappealing substance, sealing it in a plastic bag, and then discarding it in the trash. Disposal of pharmaceutical waste must be conducted in accordance with local regulations.